Therapeutics formulated to target cancer stem cells: Is it in our future?

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Clayton, Stephanie ^a   Mousa, Shaker A ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer Stem CellCancer Stem Cell LikeMolecular SignatureCell Surface MarkersMicroenvironmentTargeted TherapyChemoresistanceCancer Recurrence; Signaling Pathways

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BMS 833923; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; LDE 225; MITOXANTRONE; MK 0752; PF 03084014; PF 04449913; QLT 0267; RAPAMYCIN; RO 4929097; SIMVASTATIN; TACROLIMUS; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BASAL CELL CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STEM CELL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LEUKEMIA; MEDULLOBLASTOMA; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; SOLID TUMOR; STEM CELL; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953113373     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-7     Document Type: Review

References (44)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-7. 10.1038/nm0797-730, 9212098.
2. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007, 21(14):3777-85. 10.1096/fj.07-8560rev, 17625071.
3. Karp JE, . ed Acute Myelogenous Leukemia 2007, Humana Press: Totowa, ed.
4. ten Cate B, et al. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets 2010, 11(1):95-110. 10.2174/138945010790031063, 20017722.
5. ten Cate B, et al. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23(8):1389-97. 10.1038/leu.2009.34, 19262596.
6. Milligan DW, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006, 135(4):450-74. 10.1111/j.1365-2141.2006.06314.x, 17054678.
7. Leith CP, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89(9):3323-9.
8. Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93(11):3678-84.
9. Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19(13):3244-54.
10. Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104(7):1442-52. 10.1002/cncr.21326, 16116598.
11. Lowenberg B, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010, 115(13):2586-91. 10.1182/blood-2009-10-246470, 20103782.
12. Walter RB, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007, 109(10):4168-70. 10.1182/blood-2006-09-047399, 1885511, 17227830.
13. Jawad M, et al. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24(1):74-80. 10.1038/leu.2009.199, 19776761.
14. Zhao X, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010, 95(1):71-8. 10.3324/haematol.2009.009811, 2805740, 19648166.
15. van Rhenen A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110(7):2659-66. 10.1182/blood-2007-03-083048, 17609428.
16. Tang R, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 2008, 8:51. 10.1186/1471-2407-8-51, 2258302, 18271955.
17. Latagliata R, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008, 143(5):681-9. 10.1111/j.1365-2141.2008.07400.x, 18950458.
18. Robert G, Fenton DLL. Cancer Cell Biology and Angiogenesis 2008, The McGraw-Hill Companies, Inc.
19. Martelli AM, et al. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol 2010, 25(5):669-80.
20. Martelli AM, et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009, 18(9):1333-49. 10.1517/14728220903136775, 19678801.
21. Sirolimus
22. Bleau AM, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4(3):226-35. 10.1016/j.stem.2009.01.007, 19265662.
23. Goodell MA, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183(4):1797-806. 10.1084/jem.183.4.1797, 2192511, 8666936.
24. Bapat S, . ed Cancer Stem Cells: Identification and Targets 2009, 29-45. John Wiley & Sons: Hoboken, 73-81, ed.
25. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-510. 10.1038/onc.2008.245, 18794884.
26. Muranyi AL, Dedhar S, Hogge DE. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res 2010, 34(10):1358-65. 10.1016/j.leukres.2010.01.006, 20193963.
27. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28(6):1075-83. 10.1200/JCO.2009.25.3641, 2834432, 20085938.
28. Hess G, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27(23):3822-9. 10.1200/JCO.2008.20.7977, 19581539.
29. Hainsworth JD, et al. Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 2010, 28(13):2131-6. 10.1200/JCO.2009.26.3152, 20368560.
30. Ghobrial IM, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010, 28(8):1408-14. 10.1200/JCO.2009.24.0994, 2834498, 20142598.
31. Pandolfi PP. Breast cancer--loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351(22):2337-8. 10.1056/NEJMcibr043143, 15564551.
32. Peng C, et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010, 115(3):626-35. 10.1182/blood-2009-06-228130, 2810991, 19965668.
33. Von Hoff DD, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(12):1164-72. 10.1056/NEJMoa0905360, 19726763.
34. Rudin CM, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361(12):1173-8. 10.1056/NEJMoa0902903, 19726761.
35. Hofmann I, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4(6):559-67. 10.1016/j.stem.2009.03.016, 3065323, 19497284.
36. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009, 61(4):290-302. 10.1016/j.addr.2009.02.005, 19249331.
37. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007, 67(15):7386-94. 10.1158/0008-5472.CAN-07-0993, 17671209.
38. Chen R, et al. Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med Oncol 2010,
39. Li R, et al. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010, 4(3):1399-408. 10.1021/nn9011225, 20148593.
40. Li GY, et al. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother 2009, 63(8):566-70. 10.1016/j.biopha.2008.10.008, 19095404.
41. Balyasnikova IV, et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One 2010, 5(3):e9750. 10.1371/journal.pone.0009750, 2841188, 20305783.
42. Wei Z, et al. Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res 2009, 28:141. 10.1186/1756-9966-28-141, 2779804, 19883517.
43. Mishima K, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001, 61(14):5349-54.
44. Morrison R, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011, 2011:941876. 2958340, 20981352.